Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, ≥2 years of age and ≤17 years of age, of any race or ethnicity~* Must have clinical diagnosis of mild to moderate atopic dermatitis (AD) at both Screening and Baseline Visits, defined as IGA score of 2 or 3 (Hanifin and Rajka, Rothe 1980)~* Must have AD affecting ≥ 5% total body surface area (TBSA) at Baseline~* History of AD for at least 3 months prior to Baseline~* Informed consent/assent in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline (21 CFR §50.25\[c\]) and applicable regulations, before completing any study-related procedures~Exclusion Criteria:~* Use of topical corticosteroids within 7 days prior to Baseline~* Use of systemic corticosteroids, topical calcineurin inhibitors, photo-therapy (eg, PUVA, UVB) or immunosuppressive therapy (eg, cyclosporine) within 14 days prior to Baseline~* Subjects that require systemic therapy for the treatment of atopic dermatitis~* Use of systemic anti-infective or antibiotic treatment within 14 days prior to Baseline~* Subjects who present with clinical conditions other than AD that may interfere with the evaluation (eg, generalized erythroderma, acne, Netherton's Syndrome, psoriasis)~* Secondary infection of AD (bacterial, viral or fungal) within the skin area under study or open skin infections in any area at Baseline~* Women of childbearing potential who are lactating or pregnant as determined by urine pregnancy test at Screening. • History of MRX-6 cream 2% sensitivity or to any component of the test article~* History of severe anxiety and/or depression; any history of suicide attempt~* Subjects with a history of human immunodeficiency virus (HIV) as determined by medical history~* Subjects with any screening clinical laboratory result outside the normal range that is clinically relevant in the opinion of an appropriately qualified physician~* Subjects who, in the opinion of the Investigator, would be non compliant with the visit schedule or study procedures~* Participation in any other investigational trial within 6 weeks of Baseline, or during study conduct~* Chronic condition(s) which are either unstable or not adequately controlled~* Use of non-sedating anti-histamines within 7 days of first dose or at any time during study conduct~* Drug or alcohol abuse, mental dysfunction, or other condition limiting the subject's ability to be compliant with study-related procedures

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): BID
- MRX-6 (Type: EXPERIMENTAL): BID

Based on this trial design, predict the completion outcome and termination type (if applicable).